Genetic susceptibility to inflammatory bowel disease: should we be looking to the hypothalamus?
M. Allocca,D. Caldirola,A. Dal Buono
DOI: https://doi.org/10.1080/1744666X.2021.1933443
2021-05-28
Expert Review of Clinical Immunology
Abstract:Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are progressive and disabling inflammatory disorders of the intestine. The precise etiology of IBD is still unknown. However, the disease pathogenesis may be triggered by the interaction between genetic susceptibility, environmental factors, and gut microbiota, resulting in a dysregulated immune response to bowel damage. Concerning genetic factors, IBD are considered polygenic disorders. A family history of IBD is the most important independent risk factor for the disease: about 12–15% of the patients report having a first-degree relative suffering from the same disease [1]. Moreover, monozygotic twins have concordance rates of 6–13% [2]. In the last decade, genome-wide association studies (GWAS) have identified more than 200 genetic loci for IBD, many of which are implied in microbiological sensing, microbiome–host interactions, innate immunity, and T-cell regulation (i.e. HLA, NOD2, Il23R, STAT3, JAK2, etc.) [3–5]. Beyond the recognized immunological mechanisms, there is a growing body of evidence supporting a link between IBD and stress, depression and anxiety-spectrum disorders. Crosssectional prevalence rates of depressive and anxiety disorders among patients with IBD range from 15% to 40% and from 20% to 30%, respectively, that are higher than expected in the general population worldwide [6,7]. Rates of depressive or anxiety symptoms are even higher, reaching 50% [6,7]. The burden of depressive or anxiety comorbidity is associated with an increased risk of flares, hospitalization, and surgery, resulting in a worse course and prognosis [8]. Whether mental disorders are consequent to IBD development or share the same pathogenesis and/or causative agents is still debated. However, recent longitudinal evidence pointed to a bidirectional relationship between mental disorders and IBD, likely related to interconnections between the neuroendocrine network, the autonomous nervous system, and the gastrointestinal tract, within the brain-gut axis [9–11]. Mental disorders, especially depression, present pathophysiological mechanisms similar to IBD, including increased proinflammatory cytokines and C-reactive protein (CRP), oxidative stress, gut permeability, and dysbiosis [12]. Many inflammatory signaling pathways (i.e. IL1-6, IL-23 and CRP) partially arise from the parasympathetic and hypothalamus-pituitary-adrenal (HPA) axis dysregulation that has been found in mental disorders, including schizophrenia, bipolar disorders, and depression [12]. Furthermore, antidepressants’ (i.e. SSRI, TCA or SNRI) beneficial effects on the IBD course or development are thought to be related not only to a general relief of depressive or anxiety symptoms but mainly to their anti-inflammatory properties and capability of increasing the parasympathetic anti-inflammatory activity [11]. Taken together, this evidence suggests that shared pathways may contribute to the interactions between mental disorders and IBD. In line with this, some authors suggest that depressive symptoms can be even considered as an ‘extra-intestinal manifestation’ of inflammation [10]. Because HPA axis plays a crucial role in the endocrine, immune, and neural crosstalk between gut and brain, its involvement in functional and genetic susceptibility to IBD deserves investigation, as well as it is a plausible candidate in the connection of IBD with mental disorders. In this paper, we examine and summarize the role of the HPA axis in the pathogenesis of IBD, emphasizing the latest evidence on the genetic predisposition of loci involved in this pathway.
Medicine,Biology